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ferumoxytol is an ultrasmall super paramagnetic particles of iron oxide (USpio) agent recently used 
for magnetic resonance (MR) vascular imaging. other USpios have been previously used for assessing 
inflammation within atheroma. We aim to assess feasibility of ferumoxytol in imaging carotid atheroma 
(with histological assessment); and the optimum MR imaging time to detect maximum quantitative 
signal change post-ferumoxytol infusion. ten patients with carotid artery disease underwent high-
resolution MR imaging of their carotid arteries on a 1.5 T MR system. MR imaging was performed before 
and at 24, 48, 72 and 96 hrs post ferumoxytol infusion. Optimal ferumoxytol uptake time was evaluated 
by quantitative relaxometry maps indicating the difference in T2* (Δt2*) and t2 (Δt2) between 
baseline and post-Ferumoxytol MR imaging using 3D DANTE MEFGRE qT2*w and iMSDE black-blood 
qt2w sequences respectively. 20 patients in total (10 symptomatic and 10 with asymptomatic carotid 
artery disease) had ferumoxytol-enhanced MR imaging at the optimal imaging window. 69 carotid MR 
imaging studies were completed. Ferumoxytol uptake (determined by a decrease in Δt2* and Δt2) 
was identified in all carotid plaques (symptomatic and asymptomatic). Maximum quantitative decrease 
in Δt2* (10.4 [3.5–16.2] ms, p < 0.001) and Δt2 (13.4 [6.2–18.9] ms; p = 0.001) was found on carotid 
MR imaging at 48 hrs following the ferumoxytol infusion. Ferumoxytol uptake by carotid plaques was 
assessed by histopathological analysis of excised atheroma. ferumoxytol-enhanced MR imaging using 
quantitative 3D MR pulse sequences allows assessment of inflammation within carotid atheroma in 
symptomatic and asymptomatic patients. The optimum MR imaging time for carotid atheroma is 48 hrs 
after its administration.
Immune-mediated inflammation1 and related neovascularization2 play crucial role in the progression of athero-
sclerotic disease processes3. Macrophages are the major inflammatory mediators of this process4 which become 
concentrated at the plaque shoulder and necrotic lipid core that makes the plaque more vulnerable to rupture and 
thromboembolic sequelae5.
Magnetic resonance (MR) imaging using targeted contrast medium such as ultrasmall superparamagnetic 
particles of iron oxide (USPIOs) have demonstrated promising results in investigating the pathophysiology of 
atherosclerosis6,7 and in the assessment of the effectiveness of anti-atherosclerotic treatments8. The physiochem-
ical properties of USPIOs attribute to their effective uptake by macrophages and their longer plasma half-life 
makes them suitable for atheroma imaging. The superparamagnetic core of USPIOs alters the magnetic suscep-
tibility by creating an imbalance of the externally applied magnetic field, which in turn leads to signal reduction 
on T2 and T2*-weighted MR images. The areas containing these particles display rapid transverse relaxation and 
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present as hypointense signal changes (i.e. negative contrast) on T2 and T2* weighted imaging and reduction in 
quantitative T2 and T2* relaxation times.
Several MR imaging studies have demonstrated the optimal time window for detection of macrophages fol-
lowing the infusion of ferumoxtran-10 in patients with carotid atherosclerotic disease9,10. USPIO-enhanced MR 
imaging has also effectively demonstrated the systemic inflammatory nature of atherosclerosis affecting various 
arterial beds simultaneously6. Using serial USPIO-enhanced MR imaging over a 3-month period in symptomatic 
patients, a significant reduction in carotid plaque inflammation with high-dose statin-lowering therapy compared 
with low-dose therapy had also been reported8. Despite, having potential benefit for imaging atherosclerotic tis-
sue and having an acceptable safety profile, Ferumoxtran-10 is no longer available.
Ferumoxytol (AMAG Pharmaceuticals, Lexington, MA, USA) is a USPIO that has obtained approval in 
the treatment of iron deficiency anaemia in patients with chronic renal failure. Ferumoxytol holds promise as 
an MR CM, however, it differs from Ferumoxtran-10 in various physicochemical properties. The plasma half 
-life of Ferumoxytol is (10–14 hrs) compared to (≈ 24 hrs) of Ferumoxtran-10 and it has different relaxivity 
(r1 = 15 mM−1s−1, r2 = 89 mM−1s−1) and r1 = 9.9 mM−1s−1, r2 = 65 mM−1s−1 respectively)11. Based on these differ-
ences, it can be hypothesised that ferumoxytol has a different optimal post-infusion imaging window.
Previously, there have been reports of the use of ferumoxytol in assessing arterial wall inflammation in carotid 
arteries12 and in aorta13. These studies however did not assess temporal dependence of ferumoxytol i.e. optimal 
imaging time post administration. Semi quantitative MR pulse sequences were used which also have limitations 
as discussed below. In the absence of the key temporal dependence information of ferumoxytol (aorta and/or 
carotid), it has been quiet premature to conduct any large scale study14, making the methodology of the study 
flawed and results unreliable.
In this study we aim to:
 (1) Determine whether ferumoxytol can be used for MR imaging of carotid plaques.
 (2) Assess the optimum MR imaging time to detect maximum signal change post ferumoxytol administration, 
using 3D qT2 and qT2* imaging.
 (3) To assess the ferumoxytol enhanced-MR imaging quantified signal drop (representative of underlying 
plaque inflammation) within carotid atheroma in the patients with symptomatic and asymptomatic carotid 
artery disease.
Methods
Ten consecutive patients (8 males and 2 females) with moderate to severe duplex-ultrasound confirmed 
carotid artery disease (i.e. 50–99%) were recruited in the first part of study. Each patient underwent a baseline 
pre-ferumoxytol MR imaging; and post-ferumoxytol MR imaging was performed at 24, 48, 72 and 96 hrs follow-
ing infusion for assessing feasibility of this imaging method and to calculate the temporal dependence.
In the second part of this exploratory study, 10 symptomatic and 10 asymptomatic patients with moderate to 
severe Duplex US confirmed carotid artery disease (i.e. 50–99%) had been recruited in total. Recruitment was 
consecutive. Among these 20, 10 had already been participants of the initial temporal dependence study. Each 
patient underwent a baseline pre-ferumoxytol MR imaging; and post-ferumoxytol MR imaging was performed 
at the optimal MR imaging time as determined by the temporal dependence investigation
This study was approved by the central Cambridge research ethics research committee. All methods were 
performed in accordance with the relevant guidelines and regulations. All study participants provided written 
informed consent.
A >50% internal carotid artery stenosis by duplex ultrasound [based on North American Symptomatic 
Carotid Endarterectomy Trial criteria] and ability to sign informed consent were necessary requirements for 
inclusion. Exclusion criteria were (i) history of atopy, asthma or allergic reaction to contrast media, iron or dex-
tran, (ii) known and documented history of haemochromatosis (iii) patients with immune or inflammatory con-
ditions e.g. systemic lupus erythematous, rheumatoid arthritis (iv) standard MR exclusion criteria.
MR imaging. Imaging was performed on a 1.5 Tesla whole body MR imaging system (MR450w, GE 
Healthcare, Waukesha, WI), using a 4-channel phased-array neck coil (PACC, Machnet, Roden, The Netherlands). 
Movement artefact was minimized using a dedicated vacuum-based head restraint system (VAC-LOK Cushion; 
Oncology Systems Ltd, Shrewsbury, United Kingdom) which serves to maintain the head and neck in a comfort-
able position and fix the coil position.
Localiser and 2D time-of-flight sequences were performed to locate the carotid bifurcations. The following 
pulse sequences were used: T1w images were acquired using a 3D variable refocusing flip angle fast spin echo 
sequence with Delayed Alternating with Nutation for Tailored Excitation blood suppression preparation. qT2* 
mapping was performed using a multi-echo fast gradient echo sequence using DANTE blood suppression prepa-
ration15. Six echoes were used as in our experience it is a good balance for the required imaging field of view and 
matrix size for the carotid study.
Finally, quantitative T2 (qT2) was performed with a multi-echo variable refocussing flip angle FSE 
sequence with improved Motion-Sensitized Driven-Equilibrium. The accuracy and repeatability of improved 
Motion-Sensitized Driven-Equilibrium prepared 3D variable refocussing flip angle fast spin echo for T2 mapping 
has previously been reported16. We used three echo times to generate qT2 maps after practical consideration of 
scanning time and accuracy. We believe that this sequence is the limit in terms of scan time and patient tolerance. 
This sequence is 3D with high spatial resolution which allows good determination of vessel wall plaque compo-
nents while keeping the scan time short as short as possible to minimize neck motion.
The detailed parameters of the pulse sequences used are tabulated in the Table 1.
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ferumoxytol administration. Patient’s vital signs (i.e. pulse rate, blood pressure and respiratory rate) 
were recorded at three-time intervals (within 15 minutes) before the ferumoxytol infusion. The USPIO agent, 
Ferumoxytol (AMAG, Canada) was obtained as a liquid preparation in 17 ml vials. The agent was further diluted 
in 250 ml of normal saline and administered as a slow infusion through an indwelling large bore intravenous 
cannula over 30 minutes. The dose administered was 5 mg/kg. Vitals were monitored every 10 minutes during the 
infusion and up to 30 min after the ferumoxytol administration. The physiochemical properties and safety data 
for Ferumoxytol has been published previously11,17,18.
image analysis. Initial image analysis was performed by the first author (AU) and cross-checked by two 
experienced MR readers (JHG, US) with greater than 30 yrs combined experience between them. Image quality 
was rated per vessel for each contrast weighting on a 5-point scale (1 = poor, 5 = excellent) dependant on the 
overall signal to noise ratio, clarity of the lumen and the vessel wall boundaries. Images with an image quality 
of ≤ 2 were excluded from the study.
Pre- and post-USPIO images were manually co-registered according to plaque morphology and distance from 
the carotid bifurcation at the time of imaging. Slice position relative to the carotid bifurcation were assigned 
ordinal numbers to enable pre- and post-infusion slice matching. Images were segmented on the first echo of 
the qT2 and qT2* sequences. Following the identification of the carotid plaque region on T2 and T2* weighted 
images, the lumen and vessel wall contours were manually drawn using a closed polygon to define the arterial wall 
ROI using OsiriX (OsiriX 5.5.2, Pixmeo, Geneva, Switzerland). Region of interest (ROI) was defined as a subset 
of the acquired MR image or a dataset used for identification of carotid plaque region based on morphology and 
anatomical landmarks.
A region was also drawn in an artefact-free background by the same observer, the standard deviation of this 
background region was used to quantify noise (defined as σ). A region was also drawn in the sternocleidomastoid 
muscle and the mean signal intensity was reported Swall. The SNR was calculated using a four-channel phased 
array correction factor: SNRwall = 0.659 × Swall/σ19.
Digital Imaging and Communications in Medicine images were imported into an in-house software devel-
oped in Matlab (The Math Works, Version R2013b, Natick, MA, USA) to perform T2*and T2 quantification. 
ROI files were exported from OsiriX and were imported into in-house Matlab software to generate quantitative 
relaxometry maps (T2*/R2*, T2/R2) and to calculate the mean T2* and T2 values.
Histological analysis. Carotid plaques of patients scheduled for carotid endarterectomy were retrieved and 
processed according to the protocol designed by the consultant histopathologist (AC) to assess for the presence 
of ferumoxytol within atheroma. The specimen was placed in formalin and following overnight fixation place in 
Ethylenediaminetetraacetic acid for approximately 24 hrs for decalcification if necessary. Subsequently, 3 mm 
transverse sections were cut through the specimen and multiple slices were processed in a cassette. These pro-
cessed specimens were embedded in paraffin blocks. From these blocks further 4 sections were cut at 3.5 micro-
metres. These sections were dehydrated and underwent haematoxylin and eosin (H&E), Perls reagent, elastin van 
Gieson (EVG) stains and immunostaining for macrophages (CD 68 marker). Histological sections were reviewed 
by the consultant histopathologist (AC) using a Nikon Eclipse 80i microscope at ×10, ×25 and ×40. Ferumoxytol 
accumulation was confirmed by Perls’ positive staining and histological sections were classified as positive or 
negative accordingly.
Statistical analysis. Ferumoxytol uptake was quantified by the absolute change in T2* (ΔT2*) and T2 (ΔT2) 
between the pre and post-ferumoxytol MR images measured for each arterial wall segment (ROI) with a decrease 
Contrast weighting T1w qT2* qT2
Sequence 3D Variable Refocusing Flip Angle FSE 3D multi-echo fast gradient echo
3D Variable Refocusing 
Flip Angle FSE
Acquisition plane Axial Axial Axial
Blood suppression method delays alternating with nutation for tailored excitation
delays alternating with nutation 
for tailored excitation
improved motion sensitive 
driven equilibrium
Echoes per repetition time / echo 
train length 24 6 40
Echo time(s) (ms) 15.1 4.9,10.4,15.9,21.3,26.8,32.2 26.3, 56.3, 86.3
Repetition time (ms) 580 58.1 2000
Flip angle variable 15 variable
Acquisition matrix 224 × 224 224 × 224 224 × 224
Acquisition time 5 min 47 s 7 min 52 s 8 min 55 s
Field of view (cm) 14 × 14 14 × 14 14 × 14
Pixel size (mm) 0.625 × 0.625 0.625 × 0.625 0.625 × 0.625
Slice Thickness (mm) 1.4 2.0 2.0
Number of excitations 2 1 1
Table 1. Summary of imaging parameters for the multi-contrast magnetic resonance (MR) imaging protocol at 
1.5 T.
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in T2* and T2 values indicating the ferumoxytol uptake. The analysis was quantified twice: whole plaque measure-
ments were derived from all ROIs from slices contain plaque with sufficient image quality, and this process was 
repeated using only slice matched ROIs across the multiple visits. Continuous variables are presented as median 
(interquartile range-IQR). Data normality was assessed by Shapiro–Wilk’s test. Paired Wilcoxon Signed Rank 
Test was used to compare the changes in T2 and T2* values relative to baseline examination at each follow-up 
visit. Spearman’s correlation was used to evaluate the correlation in ferumoxytol uptake at different time frames 
on both T2 and T2* images.
For the comparison between symptomatic and asymptomatic cohort of patients, analyses was performed as 
above, to obtain whole plaque measurements for the two visits. A paired t-test was used to compare the changes 
in T2 and T2* values relative to baseline and post contrast imaging session and unpaired t-test to compare the 
difference between the groups. P values <0.05 were defined as statistically significant. The statistical analysis was 
performed in R (version 3.2.1).
Results
Quantitative MR image analysis- feasibility and temporal dependence assessment. Nine of 
the ten patients completed all of the MR examinations. One patient was unable to attend the final 96 hrs imaging 
session. The patient demographics and co-morbidities are presented in Table 2. The scheduled 24, 48, 72 and 96 
post-infusion scans occurred at 24.6 ± 2.1, 48.5 ± 1.5, 73.7 ± 1.6 and 98.4 ± 1.7 hrs post-infusion.
In total 69 carotid MR imaging studies were completed, and MR images used for analyses.
Among 10 patients, 18 plaques were identified (10 right-side and 8 left-side). Signal drop was identified in all 
plaques on qT2 and qT2* sequences as shown in Fig. 1.
Mean T2 and T2* values of the whole plaque and slice matched location (see Figs. 2 and 3) on subsequent 
time points relative to baseline were used for statistical analysis. A decrease in qT2 and qT2* values was observed 
between 24–72 hrs with a positive correlation between the qT2 and qT2* values at 48 hrs post ferumoxytol infu-
sion (Spearman’s r = 0.492, p = 0.039). A significant decrease in qT2 [13.4 [6.2 to 18.9] ms, (p = 0.001)] and qT2* 
[10.4 [3.5 to 16.2] ms, (p < 0.001)] was observed at 48 hrs post ferumoxytol administration.
Using advanced 3D acquisition techniques, pixel-wise ΔT2/R2 and ΔT2*/R2* maps (R2* is the inverse of 
the mean T2*) from the pre and post contrast studies were generated (see Figs. 4 and 5). The median number of 
pixels per cross-sectional carotid wall area (mm2) was 1762 (Range: 657–3541). The minimum number of pixels 
per cross-sectional carotid wall area (mm2) was 675 which reduces the possibility of partial volume effect errors 
considering the small vessel size.
The maximum change in qT2 and qT2* relaxation is demonstrated in Tables 3 and 4 respectively.
As observed in Table 4, at 72 hrs post ferumoxytol unexpectedly small qT2* values were observed which was 
not in the case in qT2 values at the same time point (Table 3). Being an MR developmental study using a new CM, 
these unexpected results warrant further investigation in future studies.
The SNR of muscle was also observed to be unaltered between different time points for both T2 and T2* 
weighted imaging.
Histological analysis. The time from USPIO infusion to endarterectomy ranged from 48 hrs to 70 days. 
Carotid plaques were retrieved from 6 patients scheduled for surgery and from these15 histological sections 
containing plaque available for analysis. All the sections were stained with H&E and EVG stains to demonstrate 
plaque morphology.
Perls-positive staining was observed in 13 sections from 6 of 6 patients demonstrating USPIO in multiple 
dissociated regions within the plaque, including the FC, LC, plaque shoulder and adventitia of the vessel wall. 
Characteristics n (%)
Number of patients 10
Male/Female 8/2
Median age (years) (interquartile range) 73 (67–75)
Mean luminal stenosis (North American Symptomatic 
Carotid Endarterectomy Trial) (%) [IQR] 56.9 (50.2–67.4)
TIA/non-disabling stroke 10 (100%)
Hyperlipidaemia 6 (60%)
Hypertension 7 (70%)
Diabetes Mellitus 2 (20%)
Peripheral arterial disease 2 (20%)
Previous coronary revascularisation 1 (10%)
Ischaemic heart disease 3 (30%)
Atrial fibrillation 0
Statin use 10 (100%)
Clopidogrel 8 (80%)
Aspirin 6 (60%)
Current or ex-smoker 6 (60%)
Table 2. Patient demographics and comorbidities.
5Scientific RepoRtS |         (2020) 10:1808  | https://doi.org/10.1038/s41598-020-58708-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Macrophage immunostaining with CD68 antibody marker, co-localised with Perls-positive regions in all the 13 
sections from the 6 patients was observed (see Fig. 6).
These results support our group previous histopathogical findings using Ferumoxtran-1013. Neovascularisation 
adjacent to the distribution of the macrophages was also observed hence indicative of the inflammation along 
with neovessel formation (see Fig. 6).
ferumoxytol-enhanced MR imaging of patients with symptomatic and asymptomatic carotid 
artery disease. All patients (n = 20) underwent ferumoxytol-enhanced MR imaging of carotid arteries 
successfully and tolerated the ferumoxytol infusion with no side effects. Patient demographics are presented in 
Table 5. The two clinical groups of symptomatic and asymptomatic patients had comparable demographics and 
co-morbidities (Tables 5 and 6). Total imaging time was ~25 minutes.
Signal loss was identified in all plaques on qT2 and qT2* sequences. Mean T2 and T2* values of the whole 
plaque on pre- and post-ferumoxytol imaging session were used for statistical analysis.
In both symptomatic (n = 10) and asymptomatic (n = 10) patient cohorts, we observed a significant decrease 
in qT2 and qT2* values between baseline and 48 hrs post-ferumoxytol MR imaging session (∆ T2, p = 0.030; 
∆T2*, p = 0.003) and (∆T2, p = 0.002; ∆T2*, p < 0.001) respectively (see Fig. 7). The SNR of muscle was observed 
to be unaltered between different time points for both T2 and T2* weighted imaging (see Fig. 8). T2*/R2* maps for 
an asymptomatic patient are presented in Fig. 9.
Discussion
In this study we report the temporal dependence for ferumoxytol-enhanced MR imaging of human carotid ath-
eroma for the first time in published literature. The feasibility of ferumoxytol in evaluation of carotid atheroma 
using blood suppressed qT2 and qT2* 3D pulse sequences in patients with symptomatic and asymptomatic carotid 
artery disease is also reported. Previously conducted studies in various vascular territories have used different 
imaging windows following the ferumoxytol administration12,20, however the optimum MR imaging window 
post-ferumoxytol remained widely unexplored. We found signal loss occurred between 24–72hrs with a sig-
nificant statistical correlation between the qT2 and qT2* values at 48 hrs post ferumoxytol infusion. This was 
quantified using an advanced 3D acquisition technique and assessment of ΔqT2 and ΔqT2* values. The blood 
suppression technique, DANTE was utilised for T2* mapping which is superior to the previously used 2D acquisi-
tion methodologies. 3D preparation pulses achieve better blood suppression than 2D pulse sequences and allows 
3D acquisition allows larger longitudinal coverage within feasible imaging times with respect to 2D techniques10. 
Besides, the T2* weighted multi-echo fast gradient echo pulse sequence requires high uniformity of the mag-
netic field, independent of the paramagnetic substance or diamagnetic substance therefore with changes in the 
Figure 1. Detailed multi-contrast ferumoxytol-enhanced magnetic resonance imaging protocol of carotid 
atheroma demonstrating the qT2* with six echo times, qT2 with three echo times and T1 pulse sequence 
at baseline and 48hrs post ferumoxytol administration with corresponding R2* and T2*maps. This figure 
illustrates the detailed MR imaging protocol at baseline and 48 hrs after the administration of ferumoxytol in 
a patient with right internal carotid artery stenosis >70% as calculated by NASCET criteria. Panel [A] shows 
the multi-echo T2*/R2* mapping sequence with six echo times and the corresponding R2* and T2* maps before 
and at 48 hrs following the administration of ferumoxytol. Panel [B] shows the iMSDE PD and T2 mapping 
sequence and the corresponding R2 and T2 maps before and at 48 hrs following the ferumoxytol administration. 
Panel [C] demonstrates the 3D TOF (time of flight) and T1 images pre-contrast and at 48 hrs of ferumoxytol 
administration.
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uniformity of the magnetic field, the sequence is sensitive for detection of small lesions. Hence it has the ability to 
sensitively detect paramagnetic material, such as USPIO21.
This study reports the simultaneous acquisition of qT2 and qT2* 3D pulse sequences and qT2 and qT2* values 
in assessing the temporal dependency of ferumoxytol-enhanced MR imaging of carotid atheroma. To our knowl-
edge this is the first report in the published literature to have used this comprehensive quantitative analysis for 
the evaluation of ferumoxytol-enhanced MR imaging in carotid artery territory. Development of this quantitative 
mapping method has been described by our group previously15.
Previous studies used the semi-quantitative analysis technique to assess the changes in relative signal intensi-
ties of the arterial wall normalized for the signal intensity in the adjacent muscle on T2 and T2* weighted images. 
However, this approach has been criticised as the differences in patient and coil positioning during subsequent 
imaging sessions may influence signal intensities in plaque area hence may lead to false interpretation of inflam-
mation22. However, quantitative mapping techniques negate these confounding factors while enhancing the sen-
sitivity of assessment of localisation and amount of USPIO uptake in atherosclerotic tissue. Using an advanced 
3D acquisition technique, we were able to generate pixel-wise ∆T2/R2 and ∆T2*/R2* maps (R2* is the inverse of 
the mean T2*) from the pre and post contrast studies. A similar approach was recently used by another group for 
carotid imaging12. We have reported our results as decrease in qT2/qT2*, previously the comparison of the repeat-
ability of R2* values and T2* values have been experimentally determined and no evidence of bias was observed23.
We were able to quantify signal loss in all patients who had ferumoxytol-enhanced MR imaging. This positive 
finding was best visualised using a blood-suppressed 3D T2*-weighted MEFGRE sequence between 48–72 hrs 
after infusion. We observed a decrease in T2/T2* values 24 hrs after USPIO administration. This was however 
associated with artefacts caused by insufficient blood suppression most likely due to the presence of ferumoxytol 
Figure 2. Box and whisker plots of whole plaque and slice matched quantitative T2 and change in quantitative 
T2 at 24, 48, 72 and 96 hrs post ferumoxytol administration relative to baseline. Figure illustrates the qT2 
of (A) whole plaque (C) slice matched location with carotid bifurcation taken as a reference for slice match 
representing all 10 patients at baseline, 24, 48, 72 and 96 hrs post ferumoxytol administration. (B) Demonstrates 
the change in whole plaque qT2 at 24, 48, 72 and 96hrs relative to the baseline (p = 0.006), (p < 0.001), 
(p = 0.002) (p = 0.070) respectively (D) demonstrates the slice matched location change in qT2 at 24, 48, 72 and 
96 hrs relative to the baseline (p = 0.053), (p = 0.015), (p = 0.093), (p = 0.770) respectively.
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in the blood pool at this time-point. The decreased T1 of blood after ferumoxytol infusion would likely influence 
the accuracy of T2/T2* measurements at this time-point. The multi-echo fast gradient echo T2* weighted sequence 
is also sensitive to the smallest changes in magnetic field, hence when the paramagnetic contrast medium (like 
ferumoxytol) reaches the neovessel of the atherosclerotic plaque for the first time, the sequence can detect these 
changes sensitively, which appears as a decrease in signal intensity on this pulse sequence and simultaneous 
amplification of artefacts caused by insufficient blood suppression due to above reason15.
Using a quantitative approach, we observed a significant decrease in T2 and T2* values in carotid atheroma 48 
hrs after ferumoxytol administration. As a quantitative indicator, the T2* value is widely used in clinical appli-
cations. Besides providing the measurements of the T2* value of tissues on multi-echo fast gradient echo T2* 
weighted imaging it also has the ability to indirectly reflect the iron content of the tissues. The increase in iron 
content of tissues can cause a shortening in the T2* relaxation time. This is conducive to quantitatively study 
iron uptake and deposition. This technique has been previously validated for the quantitative determination of 
changes in tissue biochemical components24. This decrease in T2* and T2 was not observed in the adjacent sterno-
cleidomastoid muscle taken as a control. In this study we measured both T2 and T2* relativities and found them 
to be significantly correlated (r = 0.492) post-USPIO infusion at 48 hrs.
This fundamental information about the temporal dependence of ferumoxytol may potentially form the basis 
of use of this pharmaceutical agent in future studies aimed at assessing pathophysiology of atherosclerosis and 
atherosclerosis-related inflammation; and in determining efficacy of established and novel anti-atherosclerotic 
drugs using MR imaging studies.
Figure 3. Box and whisker plots of whole carotid plaque and slice matched quantitative T2* and change 
in quantitative T2* at 24, 48, 72 and 96 hrs post ferumoxytol administration relative to baseline. Box and 
whisker plots illustrate the qT2* of (A) whole plaque (C) slice matched location with carotid bifurcation taken 
as a reference for slice match representing all 10 patients at baseline, 24, 48, 72 and 96 hrs post ferumoxytol 
administration. (B) Demonstrates the change in whole plaque qT2* at 24, 48, 72 and 96hrs relative to the 
baseline (p < 0.001), (p < 0.001), (p = 0.154) (p = 0.091) respectively (D) demonstrates the slice matched 
location change in qT2* at 24, 48, 72 and 96 hrs relative to the baseline (p = 0.001), (p < 0.001), (p = 0.222), 
(p = 0.020) respectively.
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We also observed that signal loss was still present at 96 hrs imaging in relation to the baseline in our study. 
This was evident on the decreased qT2 and qT2* values at 96 hrs imaging session. Previously conducted studies 
have shown the washout time for ferumoxytol in another vascular bed of approximately two weeks following the 
ferumoxytol administration20. As USPIOs are composed of an iron oxide core surrounded by a thick and com-
plete dextran coat having a hydrodynamic size smaller than 50 nm. These particles remain mono-dispersed in 
solution and are withdrawn from the blood by MPS. The smaller size of these particles facilitates their extravasa-
tion through diseased microvessels, where they are engulfed and accumulated by the tissue-resident macrophages 
within the first 24 hours after the infusion25. Hence this macrophage-selective property allows imaging of vascular 
inflammation by delayed MR imaging.
Assessment of histological data revealed co-localisation of ferumoxytol and macrophages carotid atheroma. 
The presence of adjacent prominent neovessel alongside the ferumoxytol aggregation also supports the probable 
role of the nevessels in promoting macrophage recruitment because iron particles were found both within the 
adventitia and the plaque area.in areas. The exact mechanism of USPIOs uptake is however unknown.
In the second part of this exploratory study it was observed that:
 1. In the symptomatic patient cohort, signal loss was observed as significant decrease in qT2 and qT2* 
values and signal loss on qT2 and qT2* weighted pulse sequences on post-ferumoxytol MR imaging with 
p = 0.030, p = 0.003 respectively. These findings support the initial hypothesis that patients with active dis-
ease would have higher macrophage activity and inflammation within atheroma and hence greater uptake 
of ferumoxytol by these activated macrophages resulting in significant signal drop on MR imaging.
 2. It was observed that despite of the asymptomatic status of the study subjects, 90% of asymptomatic 
plaques demonstrated ferumoxytol uptake in the form of signal loss and decrease in qT2 and qT2* values 
on post-ferumoxytol MR imaging, p = 0.002 and p < 0.001 respectively. Since most of the patients in the 
asymptomatic patient cohort had moderate to severe stenosis, these findings may suggest that despite of 
their asymptomatic disease status for previous 6 months, there may be underlying inflammatory activity 
Figure 4. Oblique view of quantitative T2*mapping sequence of the carotid artery pre-contrast and 24, 48, 72 
hrs post ferumoxytol with its corresponding T2* and R2* maps. An internal carotid artery plaque occupying 
more than 70% of the lumen is evident. [A] Demonstrates images acquired by the T2*/R2*mapping sequence 
at baseline and 24, 48 and 72 hrs following ferumoxytol infusion. Note the signal void at 48hrs-72hrs (yellow 
arrow) reflecting ferumoxytol uptake, [B] shows the corresponding oblique T2* maps with relative decrease 
in T2* values and maximum decrease at 48 hrs, [C] demonstrates the corresponding increase in R2*values 
with maximum increase at 48 hrs. The maximum T2* drop was seen on 48 hrs which also corresponds to the 
maximum R2* increase at the same time frame.
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within atheroma. Also 40% of these patients had ischaemic heart disease, hence it may be inferred that 
despite of being asymptomatic in carotid territory, the inflammatory activity in the other vascular bed 
i.e. coronary bed may influence the level of inflammatory activity in carotid atheroma due to systemic in-
flammatory nature of atherosclerosis. Similar results were observed in previously conducted studies using 
ferumoxtran-10-enhanced MR imaging6.
 3. On comparative quantitative analysis of both symptomatic and asymptomatic patient cohorts on qT2w 
and qT2*w imaging, no statistical significance was observed in this comparison (∆T2, p = 0.220; ∆T2*, 
p = 0.589 respectively). This is most likely a type 2 error, attributed to the relatively small sample size. 
Future studies are warranted to investigate this in an adequately powered study.
All patients recruited in this study tolerated the ferumoxytol infusion well with no significant adverse events 
and completed the consecutive imaging sessions. All the patients were closely monitored for any signs of hyper-
sensitivity after the warning from The Food and Drug Administration on the use of ferumoxytol. We strictly 
adhered to the precautions as recommended in the guidelines by The Food and Drug Administration for the safe 
Figure 5. Ferumoxytol-enhanced magnetic resonance images of carotid atheroma with corresponding T2*/
R2* maps and T2* graphs at baseline and 24, 48, 72 and 96 hrs of ferumoxytol administration demonstrating 
the maximum R2* increase of the atherosclerotic plaque after ferumoxytol administration at 48 hrs. [A] Images 
of the multi-echo T2*/R2* MR sequence at all 5 time points with signal void in carotid atheroma (yellow arrow) 
visible at 48 hrs following ferumoxytol administration. [B] Shows corresponding R2* maps (mean R* values) 
pre-contrast and at 24 hr, 48 hr, 72 hr and 96 hr following ferumoxytol administration. Note the maximum R2* 
increase of the atherosclerotic plaque after ferumoxytol administration at 48hrs, reflecting USPIO uptake. [C,D] 
Shows the corresponding T2* maps and graphs demonstrating maximum decrease in T2* values at 48 hr.
MR Imaging qT2 (ms) ΔqT2 (ms) p-value
Baseline 45.8 [39.8 to 56.5] — —
24hr-post 31.6 [28.7 to 36.2] 13.7 [3.3 to 28.2] 0.011*
48hrs-post 31.1 [29.0 to 35.7] 13.4 [6.2 to 18.9] 0.001*
72hrs-post 31.7 [28.8 to 38.2] 12.6 [2.6 to 22.2] 0.005*
96 hrs-post 34.9 [33.7 to 42.5] 10.5 [1.9 to 17.8] 0.015*
Table 3. Quantitative T2 (qT2) changes relative to baseline examination at each follow-up visit. *Paired 
Wilcoxon Signed Rank Test, median [inter-quartiles].
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administration of this infusion. The safety data regarding the administration of ferumoxytol in our study fur-
ther strengthen the potential use of USPIOs for vessel wall imaging. Given the availability of superparamagnetic 
iron oxide, ferumoxytol-enhanced MR imaging avoids the risk of nephrogenic systemic fibrosis, which has been 
associated with the administration of gadolinium-based contrast media, hence it could be a good alternative for 
vascular imaging as supported by the recently conducted trials26,27.
Limitations
One of the potential issues relating to the uptake of ferumoxytol by macrophages is that the resulting suscepti-
bility artefact may preclude short-term follow-up with other diagnostic MR imaging sequences; this issue may 
be of particular concern for follow-up hepatic or oncologic imaging because ferumoxytol can persist in mac-
rophages for up to 2 months28. Also complete wash out of the previous dose of USPIO, allowing baseline T2* 
MR Imaging qT2* (ms) ΔqT2* (ms) p-value
Baseline 23.7 [19.9 to 25.4] — —
24hr-post 9.0 [6.9 to 13.6] 12.9 [9.5 to 16.4] <0.001*
48hrs-post 12.4 [8.3 to 15.7] 10.4 [3.5 to 16.2] <0.001*
72hrs-post 16.3 [10.6 to 28.0] 0.2 [-8.2 to 5.2] 0.832*
96hrs-post 12.9 [11.3 to 17.0] 8.7 [-0.5 to 12.2] 0.053*
Table 4. Quantitative T2* (qT2*) changes relative to baseline examination at each follow-up visit. *Paired 
Wilcoxon Signed Rank Test, median [inter-quartiles].
Figure 6. (a) Iron within ferumoxytol stained blue on Perl’s stain- back arrows (at 20 × magnification). (b) 
Immunohistochemical staining of macrophages (CD68) demonstrates the co-localization of the macrophages 
(black arrows) in the area corresponding to the ferumoxytol uptake on Perl’s stain (a). Neovessels (blue star) 
seem to be in vicinity of areas abundant in macrophages.
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to return to normal is essential to reassess uptake of USPIO accurately, without impact from previous USPIO 
administration20.
other limitations include. (1) image quality affected by poor blood suppression as ferumoxytol remains 
intravascularly within first 24 hrs, hence imaging quality between 24–36 hrs is markedly affected till the time it 
is taken up intracellularly; (2) the decrease in T1 of blood following ferumoxytol administration may affect the 
accuracy of R2*measurements; (3) An additional patient visit posing a logistical limitation with MRI scheduling; 
(4) Inter-reader and Intrareader reproducibility was not assessed in this study. The lack of formal blinding of 
imaging prior to analysis was also a limitation. Future studies are warranted to assess this. (5) The second part 
of this study, being exploratory in nature, had small sample size. This was designed as a pilot study primarily 
to assess the feasibility of ferumoxytol-enhanced MR imaging in patients with symptomatic and asymptomatic 
disease. (6) There was variable duration between a patient undergoing carotid MR and carotid endarterectomy 
(maximum 70 days). This delay in obtaining the carotid sample for histological assessment may have affected 
some histology findings, however we consistently noted co-localisation of Perl’s stained iron with areas containing 
CD68 stained macrophages. (8) There were only 2 female patients in our study sample. It remains predominantly 
an unanswered question about how the immune mechanistics differs between men and women regarding ather-
osclerosis29, and its implications for imaging studies using iron oxide contrast media for investigating atheroscle-
rosis related inflammation.
Characteristics n (%)
Number of patients 20
Male/ Female 17/3
Median age (years) (IQR) 71(66–75)
Mean luminal stenosis (North American Symptomatic 
Carotid Endarterectomy Trial) (%) [IQR] 58.7 (51.4–64.4)
Previous TIA (6 months ago) or asymptomatic 10 (50%)
Recent TIA/ nondisabling stroke 10 (50%)
Hyperlipidaemia 10 (50%)
Hypertension 17 (85%)
Diabetes Mellitus 5 (25%)
Peripheral arterial disease 2 (10%)
Previous coronary revascularisation 2(10%)





Current or ex-smoker 13(65%)
Table 5. Patient demographics.
Symptomatic 
carotid artery 
disease (n = 10)
Asymptomatic 
carotid artery 
disease (n = 10)
p-value (two-
tailed)
Age (years) 70.5 (66.5–75.2) 70 (66–75.5) 0.548†
Vascular events (TIA/Stroke) 10 (100%) 4 (40%) 0.014*
Ischemic heart disease 2 (20%) 4 (40%) 0.62*
Carotid endarterectomy 4 (40%) 4 (40%) 1.00*
Hypertension 9 (90%) 8 (80% 0.53*
Hyperlipidaemia 8 (80%) 4 (40%) 0.53*
Diabetes 3 (30%) 2 (20%) 0.60*
Statin 10 (100%) 10 (100%) 1.00*
Clopidogrel 10 (100%) 4 (40%) 0.02*
Aspirin 9 (90%) 5 (50%) 0.14*
Angiotensin-converting enzyme 
inhibitor-Inhibitor 4 (40%) 3 (30%) 0.63*
Table 6. Comparison of the demographics and comorbidities of patients with symptomatic and asymptomatic 
carotid artery disease. *Chi-square, †Mann-Whitney Test.
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Figure 7. Box and whisker plots illustrates the Ferumoxytol uptake by symptomatic and asymptomatic 
patient cohort at baseline and 48 hrs post ferumoxytol MR imaging (A) the ∆ T 2 values, p = 0.030, p = 0.002 
for symptomatic and asymptomatic patient cohort respectively. (B) The ∆T2*values, p = 0.003, p < 0.001 for 
symptomatic and asymptomatic cohort respectively.
Figure 8. Box and whisker plots illustrate signal-to-noise ratio muscle on qT2* and qT2 weighted sequences at 
pre and 48hrs post ferumoxytol MR imaging (A) SNR muscle on qT2* weighted sequence (B) SNR muscle on 
qT2 weighted sequence at baseline and 48 hrs post-ferumoxytol MR imaging sessions.
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conclusions
This study demonstrates the feasibility and temporal dependence of ferumoxytol-enhanced MR imaging of 
carotid atheroma. This was visualised as foci of signal reduction that are attributed to ferumoxytol uptake by 
macrophages which was evident on histopathological assessment. The optimum imaging window with maximum 
signal drop during serial MR imaging sessions was identified to be 48 hrs post ferumoxytol infusion. The precise 
quantifiable indicators such as T2* relaxation time may prove to be more conducive for the quantitative evalua-
tion of the physiological/pathological status of the tissues. These preliminary results are encouraging and offer a 
rationale to conduct further investigation on larger patient cohorts.
The fundamental information about the temporal dependence of ferumoxytol may potentially form the basis 
of use of this pharmaceutical agent in future studies aimed at assessing pathophysiology of atherosclerosis and 
atherosclerosis-related inflammation; and in determining efficacy of established and novel anti-atherosclerotic 
drugs using MR imaging studies.
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